general regulatory

Clinical Research Solutions

FDA Investigates Risk of Off-Label Tramadol Use in Children

FDA is investigating the use of tramadol, a narcotic-like pain reliever, in children aged 17 years and younger after learning of the “rare but serious” risk of slowed or difficult breathing....

Clinical Research Solutions

Will There Ever Be An FDA-Approved Generic Insulin?

On February 25, 2015, FDA approved Toujeo, a once-daily, long-acting recombinant insulin. A year earlier an inhaled formulation of insulin, Afrezza, was approved. These recent additions to the...

Clinical Research Solutions

Drug Development Questions And The FDA - The End Of The Black Hole

Commonly during drug development, significant issues arise for which FDA input is desired but that do not merit a full face-to-face multidisciplinary milestone meeting. In many cases, sponsors are...

Clinical Research Solutions

FDA Prepares for GDUFA Commitments with Controlled Correspondence Guidance

With the implementation of GDUFA, FDA defined the rules and specific protocol for submitting controlled correspondence to the Office of Generic Drugs (OGD) in a draft guidance published on August 27,...

Clinical Research Solutions

FDA Aims to Standardize REMS Programs

On September 23, FDA released a report regarding “Standardizing and Evaluating Risk Evaluation and Mitigation Strategies (REMS)”. This fulfills FDA’s PDUFA commitment to issue a report of findings...

Clinical Research Solutions

New 510(k) Guidance Bans 'Split Predicates'

Medical device manufacturers may need to re-think their approach to demonstrating substantial equivalence (SE) in the 510(k) notification process, due to the FDA’s recent finalization of the guidance...

Clinical Research Solutions

Monoclonal Antibody Sameness - Effects on Orphan Drug Development

We note with interest FDA’s recently released Guidance for Industry: Interpreting Sameness of Monoclonal Antibody Products Under the Orphan Drug Regulations (April 2014). The guidance summarizes the...

Clinical Research Solutions

FDA Thinking on Biosimilar Immunogenicity Issues - A Case Study Based on the Enoxaparin ANDA Approval

Following extensive marketing of Lovenox® (enoxaparin sodium), a low-molecular weight heparin, a number of biosimilar versions of enoxaparin and one ANDA-approved formulation (enoxaparin sodium,...

Clinical Research Solutions

What Can Testosterone Gels Teach Us About Abuse-Deterrent Opioids?

For most drugs, the process of developing and obtaining FDA approval of a generic version is simple and well-defined: sponsors must only prove that their product is pharmaceutically equivalent and...

Clinical Research Solutions

Rethinking the OTC Monograph System

When the OTC drug review was undertaken in the 1970s, it was deemed the best solution available at the time for efficiently assessing the safety and efficacy of the countless drug products being sold...

Prev 3 4 5 6 7